利妥昔单抗局部注射治疗原发性眼附属器MALT淋巴瘤初步观察
该回顾性系列病例研究纳入8例原发性眼附属器MALT淋巴瘤患者,均接受病变大部分切除术后行利妥昔单抗局部注射(每3周1次,4-6次为一疗程)。随访9-30个月,所有患者病变均控制且无复发,局部及全身不良反应可耐受,结论认为该疗法对无全身侵犯的局限性POAML简便有效。
要点
- 利妥昔单抗局部注射可用于全身无侵犯的局限性POAML。
- 8例患者随访9-30个月病变均控制且无复发。
- 不良反应包括局部疼痛、红肿、发热等,均可自行消退。
核心结论
- 利妥昔单抗局部注射是治疗全身无侵犯的局限性原发性眼附属器MALT淋巴瘤的简便有效方式。
研究设计与样本
- 回顾性系列病例研究,纳入2017年9月至2018年12月郑州大学第一附属医院8例POAML患者,男3例女5例,年龄35-83岁,中位58岁。
- 所有患者接受病变大部分切除手术,病理确诊MALT淋巴瘤且CD20+,经检查排除全身病灶。
- 结膜型行结膜下浸润注射,泪腺型和眼眶型经眼球周围间隙多点注射,每3周1次,4-6次为一疗程。
主要发现
- 8例中结膜型2例(双眼病变1例)、泪腺型1例、眼眶型5例,注射2-7次,总剂量45-280 mg。
- 局部疼痛8例、局部红肿1例、发热2例、轻度胃肠道反应1例、乏力1例、心慌不适1例,均自行消退未特殊处理。
- 随访9-30个月(中位20个月),病变全部控制无复发;MRI显示局部病变完全消失5例,遗留结膜和眼外肌增厚3例。
- 全血细胞计数、血清β2微球蛋白和乳酸脱氢酶均未见异常。
关键数值与推荐
- 注射剂量为每次1.5-5.0 ml(15-50 mg),每3周1次,4-6次为一治疗周期。
- 注射范围包括或超过病变区域,根据残留肿瘤考虑是否补充治疗次数。
临床怎么用
- 对于全身无侵犯的局限性POAML,在手术大部分切除后可行利妥昔单抗局部注射。
- 结膜型采用结膜下浸润注射,泪腺型和眼眶型经眼球周围间隙多点注射(间隔1 cm),注射后加压包扎。
- 治疗期间需记录局部反应、全身反应指标及全身复发指标,对症处理不良反应。
局限性
- 回顾性系列病例研究,样本量小(8例),随访时间有限(9-30个月),无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To observe the efficacy of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (POAML). Methods: Retrospective case series study. The clinical and follow-up data of eight patients with POAML in the treatment group from September 2017 to December 2018 at the First Affiliated Hospital of Zhengzhou University were collected and analyzed retrospectively. The patients (3 males and 5 females) were 35 to 83 years old, with a median of 58 years. All patients received surgical treatment (most of the tumor were removed). The diagnosis of mucosa-associated lymphoid tissue lymphoma was confirmed by histopathology and immunohistochemical staining showed CD20+. Examinations such as chest CT, abdominal CT, bone marrow biopsy or positron emission tomography-CT to exclude lymphoma with systemic lesions. Patients with conjunctival POAML were injected through the subconjunctival infiltration. For the lacrimal gland POAML and the orbital POAML, the injection was performed through the periocular space by using a post-bulb syringe needle at multi-points with an interval of 1 cm, before the pressure dressing. All patients were injected 1.5 to 5.0 ml (15 to 50 mg) once every three weeks, 4 to 6 times as a treatment cycle. The injection range included or exceeded the lesion area. Then consider whether to supplement the number of treatments based on the remaining tumor. The patients' treatment doses, drug onset time, tumor regression, local reactions (local pain and swelling), systemic reaction indicators (fever, gastrointestinal reactions, complete blood count and the lymphocyte subsets), and systemic recurrence indicators (serum β2 microglobulin and lactate dehydrogenase detecting) were recorded. Results: Two patients, including one patient with bilateral lesions, had conjunctival POAML, one patient had lacrimal gland POAML, and five patients had orbital POAML. They received 2 to 7 injections, and the total dose was 45 mg to 280 mg. There were tolerable local pain upon injections in all patients, local redness and swelling in one patient, fever in two patients, mild gastrointestinal reactions in one patient, fatigue in one patient, and palpitation and discomfort in one patient. After close observation or corresponding symptomatic treatment, the symptoms subsided. No special treatment was given. The follow-up time was 9 to 30 months, and the median was 20 months. The lymphomas in all patients were controlled without recurrence. The MRI showed that local lesions disappeared completely in five patients, and the conjunctiva and the extraocular muscle became thickened in three patients. There was no abnormity in complete blood count, serum β2 microglobulin and lactate dehydrogenase. Conclusion: The intralesional rituximab administration is a simple, effective therapy for localized POAML with no systemic invasion. (Chin J Ophthalmol, 2020, 56: 839-845). 目的: 观察利妥昔单克隆抗体(单抗)局部应用对原发性眼附属器黏膜相关淋巴组织型(MALT)淋巴瘤的治疗效果。 方法: 回顾性系列病例研究。收集2017年9月至2018年12月于郑州大学第一附属医院眼科诊治并接受局部注射利妥昔单抗治疗的8例原发性眼附属器MALT淋巴瘤患者的临床及随访资料。患者中男性3例,女性5例,年龄35~83岁,年龄中位数为58岁。所有患者均接受病变大部分切除手术,组织病理学确诊为MALT淋巴瘤,且免疫组织化学染色均提示CD20+;经胸腹部CT、骨髓活检或正电子发射断层显像-CT等检查排除全身其他病灶。局部注射利妥昔单抗治疗:结膜型患者行结膜下浸润注射;泪腺型和眼眶型患者通过眼球周围间隙行眼眶内多点注射。记录利妥昔单抗治疗剂量、药物起效时间、肿瘤消退情况;局部疼痛、肿胀等局部反应情况;发热、胃肠道反应、全血细胞计数等全身反应指标及血清β2微球蛋白和乳酸脱氢酶等淋巴瘤全身复发指标结果。 结果: 8例患者中结膜型患者2例(其中双眼病变1例),泪腺型患者1例,眼眶型患者5例。利妥昔单抗局部注射治疗次数2~7次,总剂量为45~280 mg。局部疼痛8例、局部红肿1例、发热2例、轻度胃肠道反应1例、乏力1例、心慌不适1例。所有患者经严密观察或相应对症处理后,症状自行消退,均未给特殊处理。随访9~30个月,中位数为20个月,8例患者病变全部控制,均未见复发;MRI检查显示局部病变完全消失5例,遗留局部结膜和眼外肌增厚3例;全血细胞计数、血清β2微球蛋白和乳酸脱氢酶均未见异常。 结论: 利妥昔单抗局部注射可用于治疗全身无侵犯的局限性原发性眼附属器MALT淋巴瘤,是一种简便、有效的治疗方式。(中华眼科杂志,2020,56:839-845).
引用
- Yang JP, Pang X, Zhang K, et al. [The preliminary observation of intralesional rituximab administration in primary ocular adnexal mucosa-associated lymphoid tissue lymphoma]. Zhonghua Yan Ke Za Zhi. 2020. PMID: 33152842. doi:10.3760/cma.j.cn112142-20200215-00067
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。